33893-36-6

Basic information

• Product Name: N-phenethylmethanesulphonamide
• Synonyms: N-phenethylmethanesulphonamide;N-(2-Phenylethyl)methanesulfonamide;N-Phenethylmethanesulfonamide;N-Phenethylmethanesulphonamide(WX682926)
• CAS NO: 33893-36-6
• Molecular Formula: C₉H₁₃NO₂S
• Molecular Weight: 199.27002
• EINECS: 251-724-0
• Mol File: 33893-36-6.mol

Chemical Properties

• Boiling Point: 332.7°Cat760mmHg
• Flash Point: 155°C
• Appearance: /
• Density: 1.181g/cm³
• Vapor Pressure: 0.000143mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: N-phenethylmethanesulphonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-phenethylmethanesulphonamide(33893-36-6)
• EPA Substance Registry System: N-phenethylmethanesulphonamide(33893-36-6)

Safety Data

• Hazardous Substances Data: 33893-36-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H13NO2S/c1-13(11,12)10-8-7-9-5-3-2-4-6-9/h2-6,10H,7-8H2,1H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 64-04-0 phenethylamine 
• 54769-22-1 1-methanesulfonyloxy-1,2,3-benzotriazole 

Downstream Products

• 375346-00-2 [4-[2-[(methylsulfonyl)amino]ethyl]phenyl]boronic acid 
• 353235-95-7 N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl))phenyl)ethyl)amine 
• 375345-95-2 {(2R)-2-[4-(4-{2-[(methylsulfonyl)amino]ethyl}phenyl)phenyl]-propyl}[(methylethyl)sulfonyl]amine 
• 516491-32-0 N,N'-([1,1'-biphenyl]-4,4'-diyldi-2,1-ethanediyl)-bis-methanesulfonamide 
• 375345-99-6 N-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]ethyl]methanesulfonamide 
• 344462-93-7 N-carbamic acid tert-butyl ester-N-methanesulfonamide-N-phenethyl-4-boronic acid 
• 353235-94-6 N-(t-butoxycarbonyl)-N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 
• 353235-93-5 N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 

Relevant articles and documents

Modulators of hERAP2 discovered by high-throughput screening

Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it is involved in antigen processing. It has been linked to the risk of development of spondyloarthritis, and it associates with the immune infiltration of tumours and strongly predicts the overall survival for patients receiving check-point inhibitor therapy. While some selective inhibitors of its homolog ERAP1 are available, no selective modulator of ERAP2 has been disclosed so far. In order to identify such compounds, we screened an in-house focused library of 1920 compounds designed to target metalloenzymes. Structure-Activity Relationships and docking around two hits led to the discovery of selective inhibitors of ERAP2. Amid those, some bind to yet untapped amino-acids in the S1 pocket. Importantly, we disclose also the first activator of small substrates hydrolysis by ERAP2. Inhibitors and activators identified in this study could serve as useful starting points for optimization.

Metal-free reductive cleavage of C-N and S-N bonds by photoactivated electron transfer from a neutral organic donor

A photoactivated neutral organic super electron donor cleaves challenging arenesulfonamides derived from dialkylamines at room temperature. It also cleaves a)ArC-NR and b)ArN-C bonds. This study also highlights the assistance given to these cleavage reactions by the groups attached to N in (a) and to C in (b), by lowering LUMO energies and by stabilizing the products of fragmentation. Radical fragmentations: Electron transfer from the photoactivated neutral electron donor 1 delivers high yields of S-N and C-N cleavage products for a range of nitrogen-containing species. These reactions proceed at room temperature and under mild reaction conditions in the absence of any metal reagents. DMF=N,N-dimethylformamide, Ts=4-toluenesulfonyl.

The effect of various zinc binding groups on inhibition of histone deacetylases 1-11

Histone deacetylases (HDACs) have the ability to cleave the acetyl groups of ε-N-acetylated lysine residues in a variety of proteins. Given that human cells contain thousands of different acetylated lysine residues, HDACS may regulate a wide variety of processes including some implicated in conditions such as cancer and neurodegenerative disorders. Herein we report the synthesis and ina vitro biochemical profiling of a series of compounds, including known inhibitors as well as novel chemotypes, that incorporate putative new zinc binding domains. By evaluating the compound collection against all 11 recombinant human HDACs, we found that the trifluoromethyl ketone functionality provides potent inhibition of all four subclasses of the Zn2+- dependent HDACs. Potent inhibition was observed with two different scaffolds, demonstrating the efficiency of the trifluoromethyl ketone moiety as a zinc binding motif. Interestingly, we also identified silanediol as a zinc binding group with potential for future development of non-hydroxamate classa I and classa IIb HDAC inhibitors.

N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY

Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-substituted-N-phenylethylsulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.

A practical and efficient method for the preparation of sulfonamides utilizing Cl3CCN/PPh3

Cl3CCN in combination with PPh3 proved to be a highly reactive reagent for the conversion of sulfonic acids to the corresponding sulfonyl chlorides in refluxing CH2Cl2. Upon reaction with amines, the corresponding sulfonamides were obtained in good to excellent yields.

Potentiators of glutamate receptors

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Cyclopentyl sulfonamide derivatives

The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Sulfonamide derivatives

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

Process for preparing biphenyl compounds

The present invention relates to a process for the preparation of a biphenyl compound comprising combining a phenyl boronic acid derivative with an halobenzene derivative in the presence of a suitable additive in a suitable organic solvent with a suitable catalyst and a suitable base.

Combination therapy for treatment of depression

The present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.